MDC1 and cancer: Moreover, the ATM inhibitor KU-60019, which dissociated the MDC1-RNF8 complex (see above, in Figure 4A), rendered BIN1-deficient (thus, cisplatin-resistant) cancer cells vulnerable to cisplatin (Figure 4E).